Sanofi’s ( SNY ) vaccines division, Sanofi Pasteur recently announced that the European Medicines Agency (EMA) has given a positive opinion on its vaccine Hexaxim ((DTaP-IPV-Hib-HepB vaccine). The positive opinion was issued by the EMA as part of a procedure to evaluate products for marketing outside EU. This was the first time the EMA issued a positive scientific opinion to a vaccine under the procedure. The EMA issued the positive opinion for approving the fully liquid Hexaxim vaccine for the protecting infants against six diseases caused by Haemophilus influenzae type b, namely: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis and invasive infections.
